<DOC>
	<DOC>NCT00239291</DOC>
	<brief_summary>To estimate the safety and tolerability of 250 mg ZD1839 given concurrently with 3D-CRT in patients with non-metastatic prostate cancer</brief_summary>
	<brief_title>Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Biopsy confirmation of localised (T2) or locally advanced (T3) prostate cancer PSA below 20 ng/mL Lymph node negative Nonmetastatic Written informed consent Well differentiated stage T2 prostate cancer (Gleason score 2 to 4) Distant or nodal metastases Prostatectomy Concomitant LHRH analog treatment Previous or concomitant antiandrogens Active ILD</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>